NCT05847569View on ClinicalTrials.gov

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

May 29, 2026

Study Completion Date

May 29, 2027

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
BIOLOGICAL

Belantamab Mafodotin

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspirate

Undergo bone marrow aspirate

PROCEDURE

Bone Marrow Biopsy

Undergo biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI scan

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER